Fotios P.
- Country
- Greece
- Department
- Allergiology Department
Research Overview
- A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria
- Efficacy and Safety of Tezepelumab in Eosinophilic Esophagitis: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
- Long-term Safety Evaluation of Sebetralstat (KVD900) for On-demand Treatment of Angioedema Attacks in Hereditary Angioedema Type I or II Patients
Data & Insights
Has run more than one trial at 104 of 286 partner sites.
Specializations
Inflammatory Respiratory Conditions
The investigator specializes in treating eosinophilic esophagitis (EoE), a chronic inflammatory disorder affecting the esophagus. Their research extends to moderate-to-severe asthma management, with particular focus on preventing lung function decline.
- Esophageal inflammatory disorders
- Respiratory function preservation
- Chronic airway inflammation
Their work involves evaluating novel therapeutic approaches for inflammatory conditions affecting the respiratory tract.
Immunological Disorders
The investigator focuses on treating Hereditary Angioedema Type I and II, exploring long-term management strategies for patients with this rare genetic condition.
- Genetic immunological disorders
- Long-term disease management
- Therapeutic safety assessment
Their research encompasses innovative treatments for hereditary immune system disorders.
Dermatological Conditions
The investigator studies Chronic Spontaneous Urticaria, evaluating new therapeutic approaches for managing chronic skin conditions and reducing urticaria activity.
- Chronic urticaria management
- Clinical symptom reduction
- Immunological skin disorders
Their work focuses on advancing treatment options for persistent dermatological conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.